Paul Stuka Acquires 20,000 Shares of InspireMD (NYSE:NSPR) Stock

InspireMD, Inc. (NYSE:NSPR) Director Paul Stuka bought 20,000 shares of the stock in a transaction dated Wednesday, May 27th. The shares were acquired at an average price of $0.88 per share, with a total value of $17,600.00. Following the completion of the purchase, the director directly owned 667,871 shares of the company’s stock, valued at approximately $587,726.48. This represents a 3.09% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Paul Stuka also recently made the following trade(s):

• On Monday, May 11th, Paul Stuka bought 10,000 shares of InspireMD stock. The shares were acquired at an average price of $1.19 per share, with a total value of $11,900.00.
• On Friday, May 8th, Paul Stuka bought 65,626 shares of InspireMD stock. The shares were acquired at an average price of $1.16 per share, with a total value of $76,126.16.
• On Thursday, May 7th, Paul Stuka purchased 6,378 shares of InspireMD stock. The shares were bought at an average cost of $1.15 per share, for a total transaction of $7,334.70.
• On Wednesday, May 6th, Paul Stuka purchased 1,517 shares of InspireMD stock. The shares were bought at an average cost of $1.12 per share, for a total transaction of $1,699.04.

InspireMD Stock Performance

Shares of NSPR stock traded up $0.02 during trading hours on Friday, hitting $0.92. 252,508 shares of the company were exchanged, compared to its average volume of 183,683. InspireMD, Inc. has a one year low of $0.86 and a one year high of $2.93. The business’s 50-day simple moving average is $1.32 and its two-hundred day simple moving average is $1.63. The stock has a market capitalization of $43.09 million, a price-to-earnings ratio of -1.23 and a beta of 0.82.

Hedge Funds Weigh In On InspireMD

A number of large investors have recently bought and sold shares of the business. Raymond James Financial Inc. lifted its holdings in InspireMD by 28.9% in the second quarter. Raymond James Financial Inc. now owns 44,604 shares of the company’s stock worth $101,000 after acquiring an additional 10,000 shares during the last quarter. Citadel Advisors LLC lifted its holdings in InspireMD by 45.0% in the third quarter. Citadel Advisors LLC now owns 37,954 shares of the company’s stock worth $91,000 after acquiring an additional 11,778 shares during the last quarter. Rosalind Advisors Inc. lifted its holdings in InspireMD by 0.6% in the second quarter. Rosalind Advisors Inc. now owns 2,289,099 shares of the company’s stock worth $5,196,000 after acquiring an additional 14,109 shares during the last quarter. XTX Topco Ltd bought a new position in InspireMD in the fourth quarter worth about $30,000. Finally, Renaissance Technologies LLC bought a new position in InspireMD in the first quarter worth about $29,000. Institutional investors own 44.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $3.00 price target (down from $4.00) on shares of InspireMD in a research report on Tuesday, May 5th. Lake Street Capital set a $4.00 price target on shares of InspireMD in a research report on Monday, May 4th. Maxim Group assumed coverage on shares of InspireMD in a research report on Monday, February 2nd. They set a “buy” rating and a $6.00 price target on the stock. Finally, Loop Capital set a $5.00 price target on shares of InspireMD in a research report on Tuesday, February 24th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat, InspireMD presently has an average rating of “Buy” and an average price target of $4.50.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.